#TriNetX
TriNetX Appoints Carnell Elliott as Chief Commercial Officer to Drive Growth#Chief_Commercial_Officer#TriNetX#Carnell_Elliott
TriNetX Appoints Carnell Elliott as Chief Commercial Officer to Drive Growth
TriNetX has appointed Carnell Elliott as Chief Commercial Officer, marking a significant growth phase for the leading healthcare data network.
third-news.com
November 17, 2026 at 2:12 PM
TriNetX Appoints Carnell Elliott as Chief Commercial Officer to Drive Growth#USA#Cambridge#Health_Tech#TriNetX#Carnell_Elliott
TriNetX Appoints Carnell Elliott as Chief Commercial Officer to Drive Growth
TriNetX announces the appointment of Carnell Elliott as Chief Commercial Officer, tasked with leading the company's sales and global healthcare partnerships.
third-news.com
November 17, 2026 at 2:12 PM
Delayed PTX was associated with a higher burden of osteoporosis and nephrolithiasis compared with early surgery from 26,946 asymptomatic PHPT patients in large retrospective study using TriNetX. Raj Roy et al. J Surg Res 2026 Nov 18 shorturl.at/sM1nN
November 19, 2026 at 9:57 AM
More than 1 in 5 patients with persistent hypercalcemia on a thiazide harbored unrecognized biochemical PHPT, yet only 4% underwent PTX from large retrospective study using TriNetX. D Gomez-Carrillo et al. Surgery 2026 Nov 6 shorturl.at/UNxwM ... high index of suspicion for PHPT in thiazide users
November 19, 2026 at 9:56 AM
Protective effects of #GLP-1RA in #AbdominalAorticAneurysm

Non-ruptured AAA
13722✅vs 13722❎
Propensity-matching
5 yr f/up

TriNetX network

Rupture 2.4➡️1.6%
Elective repair 3.0➡️2.1%
MACE 54.1➡️48.2%
All-cause mortality 20.2➡️13.0%

#JVascSurg 2026
www.sciencedirect.com/science/arti...
November 14, 2026 at 7:57 PM
【GLP-1RA関連役開始後1年で2~3%が栄養性貧血?TriNetXデータベース/DRCP】Nov. 17

過体重/肥満2型DM、PSマッチ可能だった67,608×2例比較——

・チルゼパチド開始後1年間で2.1%に「栄養性貧血」。
・GLP-1RAなら2.8%。

抄録🔗 qr.paps.jp/1i3U1
November 18, 2026 at 10:14 PM
TriNetX Introduces Human-Validated Fact Extraction for Enhanced Clinical Research#USA#Cambridge#AI_Technology#TriNetX#Clinical_Notes
TriNetX Introduces Human-Validated Fact Extraction for Enhanced Clinical Research
TriNetX has unveiled a groundbreaking human-validated fact extraction method from clinical notes, improving the reliability of clinical data for research.
third-news.com
November 10, 2026 at 4:17 PM
TriNetX Unveils Groundbreaking AI-Driven Fact Extraction from Clinical Notes#USA#Cambridge#AI_Technology#TriNetX#Clinical_Notes
TriNetX Unveils Groundbreaking AI-Driven Fact Extraction from Clinical Notes
TriNetX has launched a new capability for reliable fact extraction from clinical notes using AI, enhancing research capabilities and trust in data.
third-news.com
November 10, 2026 at 2:32 PM
GLP-1 receptor agonist use linked to lower mortality than DPP-4 or SGLT2 inhibitors in bronchiectasis with type 2 diabetes

#Bronchiectasis
GLP-1 receptor agonist use linked to lower mortality than DPP-4 or SGLT2 inhibitors in bronchiectasis with type 2 diabetes
A retrospective TriNetX cohort study found GLP-1RA use was associated with lower all-cause mortality, acute respiratory failure and lower respiratory tract infection, but not fewer bronchiectasis exacerbations.
lungdaily.org
November 15, 2026 at 8:03 AM
⭐ Abs 2861 Patel/Choi

🔎 TriNetX study of SLE

🖥️ PREVENT calculator of HF, CVD risk and its performance

🤔 I think the first time I’ve seen TriNetX used for CV risk estimation in rheum

#ACR26
November 10, 2026 at 6:05 PM
⭐ Abs 2304 Heydari Kamjani/Magrey

🔎 TriNetX study: PsA pop, looking JAKi and MACE, VTE risk

👉️TNFi and IL17i both had lower risk vs JAKi in this study but usual TriNetX platform caveats apply

#ACR26
November 10, 2026 at 2:04 PM
⭐ Abs 2646 Afshar

📊 resident led TriNetX study in T2DM

🔎 Exposure: SGLT2i vs DPPi
🔎 outcome: incident gout – RR 0.71

#ACR26
November 10, 2026 at 4:05 PM
⭐ Abs 1302 Hindoh/Vina

📊 TriNetX: PsA and GLP1-RA use

🔎 outcomes: synovitis, stiffness, pain, steroid use – will have to ask how they defined these in TriNetX because with diagnostic coding, it’s hard to capture the synovitis, stiffness, pain symptoms 🤔

#ACR26
November 9, 2026 at 2:04 PM

⭐ Abs 0712 Kasiraj

🔎 TriNetX study looking at gout & T2DM population on GLP1-RA vs DPP4i with outcomes of gout flares; HF, MACE; CKD; death

#ACR26
November 8, 2026 at 4:30 PM
⭐ Abs 1308 Mestarihi

📊 TriNetX: AS and IL-17i vs TNFi use and safety

👉️Null for MACE outcome

👏 Resident-led work

#ACR26
November 9, 2026 at 2:04 PM
⭐ Abs 1574 Chen

🔎 TriNetX target trial emulation
📊 study pop: T2DM + obesity

🔎 Exposure: GLP1-RA use vs SGLT2i
🔎 Outcomes: incident OA (HR 1.17), arthroplasty (HR 1.21)

#ACR26
November 9, 2026 at 4:31 PM
⭐ Abs 1328 Motwani

📊 SLR – PsO and PsA risk
n=11 studies

👉️protective for IL23i vs TNFi; pooled HR 0.6

📌 does include our study using TriNetX - pubmed.ncbi.nlm.nih.gov/38251522/

#ACR26
November 9, 2026 at 2:04 PM
⭐ Abs 1841 Pulipati/UNMC

📊 TriNetX study: gout & allopurinol initiators

🔎 looked at self reported race and AHS risk - goes back to the last set of ACR gout guidelines and who should get screen for HLA-B5801

#ACR26
November 9, 2026 at 1:30 PM
Smattering of #ACR26 abstracts focused on GLP1 receptor agonists.

Most of these used TriNetX and propensity score methods within the platform, so please read interpretations with caution
November 7, 2026 at 8:02 PM
⭐ Abs 1648 Neogi/Putman/Tedeschi

🔎 TriNetX to study TKR risk of CPPD+OA vs OA alone

👉️With CPPD, HR 1.29-1.53 for TKR risk vs OA alone

👉️Another study pointing to the additional impact of intra-articular crystal deposition/calcification on OA

#ACR26
November 9, 2026 at 4:31 PM
🤔 thoughtful design with the limitations of TriNetX

authors explain they expected confounding by indication to bias in the direction of RTX having higher risk of poor outcomes

#ACR26
November 8, 2026 at 9:01 PM
⭐ Abs 0801 Danagara

📊 TriNetX study

🔎 wanted to look at new IgG4RD code (10/2023) and FDA approval for inebrilizumab (4/2025)

🔎 exposure: RTX vs conventional IST

#ACR26
November 8, 2026 at 9:01 PM